Using of checkpoint inhibitors as a treatment for melanoma
Loading...
Date
2020-02-18
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
faculty of Basic Medical Science - Libyan International Medical University
Abstract
Immune checkpoint blockade has used as a treatment of patients with advanced
melanoma and many other cancers. Blockade of inhibitory receptors, cytotoxic Tlymphocyte antigen 4 (CTLA-4) and programmed cell death receptor 1 (PD-1) that
enhances T-cell-mediated antitumor immune responses leading to improved immune
responses, based on their studies and mechanism of action in the treatment of
metastatic melanoma
Description
Immune checkpoint inhibitors are drugs that help the immune system to release
“brakes” of inhibitory receptors expressed on the surface of activated T-cells,
cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death receptor 1
(PD-1) that enhances T-cell-mediated antitumor immune responses leading to
improved immune responses. Ipilimumab and Nivolumab are examples of immune
checkpoint inhibitors, where ipilimumab targets CTLA-4 and nivolumab targets PD1/PD-L1
Keywords
Citation
Collections
Endorsement
Review
Supplemented By
Referenced By
Creative Commons license
Except where otherwised noted, this item's license is described as Attribution 3.0 United States